- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Business Development Office
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel mucolytics for the treatment of respiratory diseases
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Type 1 diabetes

Type 1 diabetes occurs when the immune system attacks and destroys the beta cells in the pancreas that produce the hormone insulin. Without insulin, the level of the sugar glucose in the blood cannot be controlled.
Type 1 diabetes is a serious lifelong health condition. Our type 1 diabetes researchers are discovering how harmful immune responses damage the insulin-producing cells. This is leading to new ways to prevent and treat type 1 diabetes.
Our type 1 diabetes research
Our researchers are working to improve the prevention and treatment of type 1 diabetes. Their goals are to:
- Understand why immune cells attack insulin-producing cells.
- Understand the environmental factors that predispose to type 1 diabetes.
- Develop and trial new ways to prevent type 1 diabetes.
- Develop immune therapies to treat type 1 diabetes.
- Develop strategies to regenerate insulin-producing cells from stem cells as a cure for type 1 diabetes.
- Improve the success of pancreas transplantation as a cure for type 1 diabetes.
- Develop novel insulin analogues that will make life easier for patients with type 1 diabetes.
What is type 1 diabetes?
The amount of glucose in the blood is normally tightly controlled. But in diabetes blood glucose levels are abnormally high.
The hormone insulin normally reduces blood glucose levels and is produced by cells in the pancreas called ‘beta cells’. However, in type 1 diabetes there is a misdirected ‘autoimmune’ reaction to the insulin-producing beta cells in the pancreas, which leads to insufficient insulin being produced. Without insulin, high levels of glucose accumulate in the blood.
The immune system protects our body from invading microbes. There are normally many safeguards that prevent it from attacking the body’s own tissues. In type 1 diabetes, these safeguards fail, and immune cells specifically destroy beta cells.
Type 1 diabetes is the most common chronic (long-term) childhood illness in Australia. More than 120,000 Australians have type 1 diabetes. The incidence of type 1 diabetes in Australia has increased in the past 30 years.
Most people with type 1 diabetes are diagnosed as children or young adults. Even with a lifetime of the best available care, they are at increased risk of serious complications such as
- Kidney disease (diabetic nephropathy)
- Eye disease and blindness (diabetic retinopathy)
- Nerve damage (diabetic neuropathy)
- Damage to blood vessels, which together with nerve damage can lead to serious problems in the hands and feet
- Heart disease and stroke
Risk factors for type 1 diabetes
Type 1 diabetes is caused by a combination of genetic risk and environmental factors. Our researchers have shown that changes in our environment have contributed to the increase in the incidence of type 1 diabetes in the past few decades.
Many environmental factors have been proposed to trigger or promote type 1 diabetes. These include infections, diet and weight gain.
Known risk factors for type 1 diabetes include:
- Having other autoimmune or inflammatory diseases such as coeliac disease or autoimmune thyroid disease. These conditions all involve aberrant immune responses.
- Having a parent or sibling with type 1 diabetes or other autoimmune diseases. One in five Australians diagnosed with type 1 diabetes have a family history of the condition.
- Living at higher latitudes: the incidence of type 1 diabetes is increased in populations who live furthest from the equator. This may be partly genetic. It may also be related to environmental factors such as vitamin D deficiency and hygiene.
How is type 1 diabetes treated?
Almost all people with type 1 diabetes rely on insulin injections for their entire lives. They must closely monitor their blood glucose levels. When blood glucose rises, such as after a meal, an appropriate insulin dose is calculated and injected. Insulin is available in ‘slow acting’ and ‘fast acting’ forms. These can aid the smoother control of blood glucose levels.
There is no orally available (tablet) form of insulin. Insulin can only be given by injection, such as with a syringe. Recently, small, attachable insulin pumps have been introduced instead of multiple daily injections. Insulin pumps may control blood glucose better by providing a more steady release of insulin into the body.
The only cure for type 1 diabetes is transplantation or regeneration of insulin-producing cells.
Transplantation of the whole pancreas or the parts of the pancreas containing insulin-secreting beta cells can be performed. It is limited by a shortage of organ donors, and the need for life-long immune suppression to prevent transplant rejection. Thus, transplantation is restricted to people with poorly controlled diabetes and serious complications.
Our researchers have shown that the pancreas contains stem cells that can be transformed into beta cells. Their hope is that it may one day be possible to cure type 1 diabetes by stimulating the regrowth of beta cells. This would depend on stifling the immune cells that originally destroyed the beta cells.
Diabetes Australia has more detailed information about diabetes treatment.
Type 1 diabetes ‘vaccine’
Our research into how immune cells attack insulin-producing cells has led to a new strategy to prevent type 1 diabetes. A nasal insulin ‘vaccine’ developed by our researchers has shown promise in clinical trials for preventing the development of type 1 diabetes.
Researchers:
Super Content:
A five-year international trial has found that type 1 diabetes can be delayed by an immune therapy.
The therapy, teplizumab, delayed the onset of diabetes in participants by two years.
A drop in the number of young children diagnosed with type 1 diabetes could be associated with the introduction of routine rotavirus vaccination of Australian infants.
Australia's largest study into the causes of type 1 diabetes will track women and children from early pregnancy to three years of age.
The JDRF Lifetime Research Achievement Award recognises the long-standing nature and high quality of contributions of the very best Australian researchers who have steered global directions of type 1 diabetes research.
A landmark discovery about how insulin docks on cells could help in the development of improved types of insulin for treating both type 1 and type 2 diabetes.